FDA approves Kymriah for advanced follicular lymphoma

The FDA granted accelerated approval to tisagenlecleucel for treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Tisagenlecleucel (Kymriah, Novartis) — developed by Novartis in collaboration with University of Pennsylvania — is an autologous, gene-edited, CD19-directed chimeric antigen receptor T-cell therapy.
The agent is also approved in the U.S. for patients aged 25 years or younger with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, as well as adults with diffuse large B-cell lymphoma, high-grade

The FDA granted accelerated approval to tisagenlecleucel for treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Tisagenlecleucel (Kymriah, Novartis) — developed by Novartis in collaboration with University of Pennsylvania — is an autologous, gene-edited, CD19-directed chimeric antigen receptor T-cell therapy.
The agent is also approved in the U.S. for patients aged 25 years or younger with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, as well as adults with diffuse large B-cell lymphoma, high-grade